CTRI/2018/07/014787CompletedPhase 3
A prospective, open label, randomized controlled trial to evaluate the effect of intravenous vitamin C, Thiamine and Hydrocortisone treatment on all cause mortality among patients with severe sepsis and septic shock. - ViCTOR
Trial Snapshot
- Phase
- Phase 3
- Status
- Completed
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
Inclusion Criteria
- •Patients admitted to ICU with :
- •1)primary diagnosis of sepsis/septic shock as determined based on SSC 2012 guidelines.
- •2)Patients > 18 years of age
Exclusion Criteria
- •1)Patients < 18 years age
- •2)Pregnancy
- •3)Patients with limitations of care
- •(advanced disease with malignancy)
- •5)Acute liver failure
Investigators
Similar Trials
Not yet recruiting
Phase 3
A study to compare the effectiveness of oral mycophenolate mofetil (MMF) and tacrolimus for treating children with nephrotic syndrome which does not respond to steroids.CTRI/2012/03/002479AIIMS96
Not yet recruiting
Phase 3
To find the usefulness of physical therapy through phone to improve the physical condition of children suffering from Guillain Barre Syndrome.CTRI/2021/04/032538PGIMER
Active, not recruiting
Not Applicable
Influence of anticoagulants on microparticle formatioThe effect of the used IMPs should be investigated in critically ill patients and healthy subjectsEUCTR2011-002084-20-ATMedizinische Universität Wien; Universitätsklinik für Klinische Pharmakologie
Completed
Not Applicable
A prospective, open label, randomized, controlled trial of tocilizumab versus cyclophosphamide in patients with microscopic polyangiitisMicroscopic polyangiitisJPRN-UMIN000011244Saitama Medical Center, Saitama Medical University Department of Rheumatology and Clinical Immunology40
Active, not recruiting
Phase 1
Clinical trial to evaluate the patient preference for therapy with everolimus in combination with exemestane or capecitabine in combination with bevacizumab in patients with advanced (inoperable or metastatic) breast cancerEUCTR2013-005329-22-DEiOMEDICO AG77
